Arvinas (NASDAQ:ARVN) & NeuroSense Therapeutics (NASDAQ:NRSN) Financial Review

NeuroSense Therapeutics (NASDAQ:NRSN) and Arvinas (NASDAQ:ARVN) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, valuation, earnings, analyst recommendations, dividends, institutional ownership and risk.

Profitability

This table compares NeuroSense Therapeutics and Arvinas’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
NeuroSense Therapeutics	N/A	N/A	N/A
Arvinas	-30.77%	-14.25%	-9.31%

Analyst Ratings

This is a summary of recent ratings for NeuroSense Therapeutics and Arvinas, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NeuroSense Therapeutics	1	1	2	1	2.60
Arvinas	3	3	9	0	2.40

NeuroSense Therapeutics presently has a consensus price target of $8.50, suggesting a potential upside of 865.91%. Arvinas has a consensus price target of $14.86, suggesting a potential upside of 46.95%. Given NeuroSense Therapeutics’ stronger consensus rating and higher possible upside, equities analysts clearly believe NeuroSense Therapeutics is more favorable than Arvinas.

Volatility & Risk

NeuroSense Therapeutics has a beta of 1.6, indicating that its share price is 60% more volatile than the S&P 500. Comparatively, Arvinas has a beta of 1.79, indicating that its share price is 79% more volatile than the S&P 500.

Earnings and Valuation

This table compares NeuroSense Therapeutics and Arvinas”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NeuroSense Therapeutics	N/A	N/A	-$11.12 million	($0.54)	-1.63
Arvinas	$262.60 million	2.48	-$80.80 million	($1.28)	-7.90

NeuroSense Therapeutics has higher earnings, but lower revenue than Arvinas. Arvinas is trading at a lower price-to-earnings ratio than NeuroSense Therapeutics, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

1.0% of NeuroSense Therapeutics shares are owned by institutional investors. Comparatively, 95.2% of Arvinas shares are owned by institutional investors. 27.4% of NeuroSense Therapeutics shares are owned by insiders. Comparatively, 7.3% of Arvinas shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

NeuroSense Therapeutics beats Arvinas on 10 of the 14 factors compared between the two stocks.

About NeuroSense Therapeutics

NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company’s lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer’s, as well as under preclinical studies for the treatment of Parkinson’s disease. Its preclinical pipeline includes StabiliC for the treatment of Parkinson’s disease; and CogniC for the treatment of Alzheimer’s disease. The company was incorporated in 2017 and is headquartered in Herzliya, Israel.

About Arvinas

Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body’s own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.